Heparin and Tirofiban interaction
Heparin and Tirofiban: both prescribing labels describe an interaction that usually calls for monitoring, a dose change, or spacing the doses.
Usually manageable with monitoring or a dose change. Tell your pharmacist you take both.
What the FDA labels say
From the Heparin (Heparin Sodium) label · effective 2026-05-12
Platelet Inhibitors Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.
From the Tirofiban (AGGRASTAT) label · effective 2025-01-01
Concomitant use of fibrinolytics, anticoagulants and antiplatelet drugs increases the risk of bleeding.
Coadministration of fibrinolytics, anticoagulants and antiplatelet agents, increases the risk of bleeding.
Thrombocytopenia: Discontinue AGGRASTAT and heparin.
If thrombocytopenia is confirmed, discontinue AGGRASTAT and heparin.
Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.
Open in the checkerNot medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.